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| INTRODUCTION
Patients with type II immune mediated heparin-induced thrombocytopenia (HIT) develop antibodies to platelet factor 4 (PF4) and develop a clinical syndrome characterized by a drop in platelet count and a prothrombotic state causing venous or arterial thrombosis. 1, 2 Delayed-onset HIT is usually suspected when the platelet count fall begins after stopping heparin. Delayed-onset HIT is also suspected with worsening thrombocytopenia after heparin cessation and is considered an "autoimmune-like HIT". [3] [4] [5] [6] The platelet count nadir usually occurs between 10 and 17 days post-immunizing heparin exposure.
In some cases, the thrombocytopenia can persist for several weeks.
It is commonly reported after major surgical interventions. 4, 6, 7 These patients are typically challenging to manage due to the persistence of their HIT antibodies and as such, their platelets remain low, leaving them at risk of thrombotic and bleeding complications. It is postulated
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that trauma and the inflammatory state prime an immune response toward the immunogenic cationic PF4+ anionic heparin complex. 8 HIT commonly occurs postoperatively, likely due to the combined effect of the release of PF4 from activated platelets during surgery and the concomitant administration of heparin. 6 As such, vascular and cardiac patients have higher rates of platelet factor-4 heparin antibody seroconversion and HIT after large intraoperative doses of therapeutic heparin or prophylactic post-operative heparin. 2, [9] [10] [11] This case series aims to identify whether there is an indication for IVIG in patients with prolonged and severe thrombocytopenia not responding to conventional HIT treatments.
| CASE 1
A 49-year-old female presented with acute new onset severe bilateral claudication and occluded bilateral popliteal and tibioperoneal arteries with a large thrombus along the anterior wall of the proximal to middescending thoracic aorta. Heparin at 18 units/kg/hour was started and she underwent successful thromboembolectomies of both lower extremities and thoracic endovascular aortic aneurysm repair (TEVAR)
with stent graft placement. Her arterial thrombi were thought to be precipitated by multiple risk factors, including the use of combined oral contraceptive pills, and heterozygosity for the prothrombin gene PG20210 mutation.
On hospital day 8, the patient's platelet count dropped from 243 000/μL to 122 000/μL with a positive clinical 4T score of 6.
Heparin was stopped and an argatroban drip was started. Heparininduced antiplatelet antibodies and PF4 antibodies ELISA screen were positive at 2.79 OD and 95-97% SRA at 0.1 and 0.5 IU/mL UFH, respectively. Despite changing heparin to argatroban, platelets continued to decline. The worsening thrombocytopenia despite being having stopped heparin suggested a diagnosis of delayed onset HIT. Intravenous immunoglobulin 1 g/kg/day and methylprednisolone 1 g/kg/day were given on days 11 and 12, when platelet count fell to 11 000/μL. On day 12, the patient was found to have a symptomatic catheter associated non-occlusive right internal jugular deep vein thrombosis. The central catheter was not heparin coated.
Platelet count recovered to 81 000/μL on day 14, but began to decline again the following day ( Figure 1 ). Repeat HIT studies on day 15
remained strongly positive by ELISA with an optic density of 3.14 and SRA of 91 and 100% with 0.1 and 0.5 IU/mL UFH, respectively. Repeat computed tomography angiography on day 15 showed an aortic endograft thrombus. Platelets nadired at 5000/μL on day 18, but recovered after another dose of IVIG, reaching 150 000/μL at discharge on day 20 ( Figure 1 ).
| CASE 2
An 84-year-old female presenting with acute chest and back pain was 
| DISCUSSION

| Clinical presentation of delayed HIT
Severe thrombocytopenia is not typically seen in HIT, however it has been described in 50% of patients with delayed onset HIT. 6 In these cases, platelet counts will usually recover slowly. There are also persistently high titers of platelet-activating IgG induced by heparin as seen in this case (up to 20 days after heparin administration). 6, 7 In a published case-series of such patients, there was greater heparindependent and independent platelet activation at serial dilutions seen in cases than in control patients with typical HIT. These delayed onset HIT patients were also found to have more thrombosis and other complications including disseminated intravascular coagulation (25% of cases). 7 The strong activation of platelets seen in serologic testing even in the absence of therapeutic heparin is a characteristic feature of delayed onset HIT. 5, 6 Although our laboratory did not perform serotonin release functional assays in the absence of heparin, our suspicion of delayed onset HIT remained elevated due to persistent HIT that worsened after heparin cessation.
| IVIG in the setting of delayed onset HIT
As soon as HIT is suspected, heparin should be discontinued and an alternative anticoagulant should be initiated. Alternative agents include direct thrombin inhibitors, namely argatroban and bivalirudin. 12, 13 Guidance on the utilization of IVIG with HIT is scant; however, there are several reports of it being associated with successful results. Many of the published cases in the literature interestingly involve severe thrombocytopenia (below 25 000/μL) that was refractory to conventional therapy 4, 9, [14] [15] [16] [17] , which is suspicious for delayed onset HIT. Of particular interest, in 2014, Warkentin and Sheppard described a case where IVIG was used in a second lifetime episode of HIT after cardiac surgery with subsequent improvement in platelet counts after two rounds of IVIG, similar to our first case. 9 We experienced success with using IVIG/methylprednisolone for delayed onset HIT, when platelet count severely dropped to below 20 000/μL during the postoperative period. Platelet counts began to improve the subsequent day, with one of our patients requiring additional IVIG after platelet count dropped again, due to persistence of antibodies. Case 1 did experience a catheterassociated thrombosis and aortic endograft thrombosis after IVIG was initially infused. However, it is unclear whether these were recognized adverse reactions to IVIG versus HIT. Otherwise, we found no additional adverse reactions to systemic IVIG. Our cases support the growing evidence that IVIG is a helpful supplemental treatment to increase platelet count and interfere with activation of heparin-PF4 antibodies in cases of severe persistent HIT, also supported through in vitro analyses. 4, 18, 19 In these cases, the benefits of IVIG outweigh the thromboembolic risks.
Methylprednisolone may also have provided a benefit, difficult to distinguish from IVIG.
| CONCLUSION
Further studies should investigate IVIG as an additional treatment to aid recovery of platelets when bleeding risk is high and while awaiting recovery from severe thrombocytopenia as a result of delayed onset HIT. Biologically, there is some interest in proposing IVIG as the treatment of delayed HIT due to persistent platelet-activating IgG antibodies as the underlying cause, as was presumed in these cases.
However, cases should be selected cautiously since IVIG can also increase thromboembolic risk.
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